The B-RAF protein is often mutated in human cancers, contributing to their development. Although most known mutations stimulate its catalytic activity, others, surprisingly, impair it — yet still cause cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Davies, H. et al. Nature 417, 949–954 (2002).
Rajagopalan, H. et al. Nature 418, 934 (2002).
Singer, G. et al. J. Natl Cancer Inst. 95, 484–486 (2003).
Brose, M. S. et al. Cancer Res. 62, 6997–7000 (2002).
Cohen, Y. et al. J. Natl Cancer Inst. 95, 625–627 (2003).
Wan, P. T. C. et al. Cell 116, 855–867 (2004).
Kolch, W. Biochem. J. 351, 289–305 (2000).
Chong, H., Vikis, H. G. & Guan, K. L. Cell Signal. 15, 463–469 (2003).
Mason, C. S. et al. EMBO J. 18, 2137–2148 (1999).
Chong, H., Lee, J. & Guan, K. L. EMBO J. 20, 3716–3727 (2001).
Weber, C. K. et al. Cancer Res. 61, 3595–3598 (2001).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Morrison, D. Enzymes play molecular tag. Nature 428, 813–815 (2004). https://doi.org/10.1038/428813a
Issue Date:
DOI: https://doi.org/10.1038/428813a